BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 22914496)

  • 1. Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging.
    Sekar TV; Foygel K; Willmann JK; Paulmurugan R
    Gene Ther; 2013 May; 20(5):529-37. PubMed ID: 22914496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive theranostic imaging of HSV1-sr39TK-NTR/GCV-CB1954 dual-prodrug therapy in metastatic lung lesions of MDA-MB-231 triple negative breast cancer in mice.
    Sekar TV; Foygel K; Ilovich O; Paulmurugan R
    Theranostics; 2014; 4(5):460-74. PubMed ID: 24669276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects.
    Yu B; Zhang Y; Zhan Y; Zha X; Wu Y; Zhang X; Dong Q; Kong W; Yu X
    Oncol Rep; 2011 Jul; 26(1):255-64. PubMed ID: 21573500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human amniotic fluid-derived stem cells expressing cytosine deaminase and thymidine kinase inhibits the growth of breast cancer cells in cellular and xenograft mouse models.
    Kang NH; Hwang KA; Yi BR; Lee HJ; Jeung EB; Kim SU; Choi KC
    Cancer Gene Ther; 2012 Jun; 19(6):412-9. PubMed ID: 22498724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.
    Harvey TJ; Hennig IM; Shnyder SD; Cooper PA; Ingram N; Hall GD; Selby PJ; Chester JD
    Cancer Gene Ther; 2011 Nov; 18(11):773-84. PubMed ID: 21836632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer.
    Wang HE; Yu HM; Liu RS; Lin M; Gelovani JG; Hwang JJ; Wei HJ; Deng WP
    J Nucl Med; 2006 Jul; 47(7):1161-71. PubMed ID: 16818951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro.
    Hunt MA; Li D; Hay MP; Currie MJ; Robinson BA; Patterson AV; Dachs GU
    J Gene Med; 2012 Jan; 14(1):62-74. PubMed ID: 22147660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro.
    Nishihara E; Nagayama Y; Narimatsu M; Namba H; Watanabe M; Niwa M; Yamashita S
    Anticancer Res; 1998; 18(3A):1521-5. PubMed ID: 9673364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound-guided delivery of thymidine kinase-nitroreductase dual therapeutic genes by PEGylated-PLGA/PIE nanoparticles for enhanced triple negative breast cancer therapy.
    Devulapally R; Lee T; Barghava-Shah A; Sekar TV; Foygel K; Bachawal SV; Willmann JK; Paulmurugan R
    Nanomedicine (Lond); 2018 May; 13(9):1051-1066. PubMed ID: 29790803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.
    Bridgewater JA; Springer CJ; Knox RJ; Minton NP; Michael NP; Collins MK
    Eur J Cancer; 1995 Dec; 31A(13-14):2362-70. PubMed ID: 8652270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
    Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
    Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.
    White CL; Menghistu T; Twigger KR; Searle PF; Bhide SA; Vile RG; Melcher AA; Pandha HS; Harrington KJ
    Gene Ther; 2008 Mar; 15(6):424-33. PubMed ID: 18079753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy.
    Hayashi K; Lee JB; Maitani Y; Toyooka N; Nemoto H; Hayashi T
    J Gene Med; 2006 Aug; 8(8):1056-67. PubMed ID: 16779868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus-directed enzyme prodrug therapy using CB1954.
    Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
    Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo.
    Westphal EM; Ge J; Catchpole JR; Ford M; Kenney SC
    Cancer Gene Ther; 2000 Jan; 7(1):97-106. PubMed ID: 10678362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of cellular- and prodrug-associated factors in the bystander effect induced by the Varicella zoster and Herpes simplex viral thymidine kinases in suicide gene therapy.
    Grignet-Debrus C; Cool V; Baudson N; Velu T; Calberg-Bacq CM
    Cancer Gene Ther; 2000 Nov; 7(11):1456-68. PubMed ID: 11129288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
    Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
    J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.
    Grove JI; Lovering AL; Guise C; Race PR; Wrighton CJ; White SA; Hyde EI; Searle PF
    Cancer Res; 2003 Sep; 63(17):5532-7. PubMed ID: 14500391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential chemosensitivity of breast cancer cells to ganciclovir treatment following adenovirus-mediated herpes simplex virus thymidine kinase gene transfer.
    Li PX; Ngo D; Brade AM; Klamut HJ
    Cancer Gene Ther; 1999; 6(2):179-90. PubMed ID: 10195885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line.
    Trinh QT; Austin EA; Murray DM; Knick VC; Huber BE
    Cancer Res; 1995 Nov; 55(21):4808-12. PubMed ID: 7585511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.